Babaodan overcomes cisplatin resistance in cholangiocarcinoma via inhibiting YAP1

IF 3.9 3区医学 Q1 MEDICAL LABORATORY TECHNOLOGY

Pharmaceutical Biology Pub Date : 2024-04-04 DOI:10.1080/13880209.2024.2331060

Jiong Li, Xiangjun Ma, Faying Xu, Yuanliang Yan, Weiqing Chen

引用次数: 0

Abstract

Cholangiocarcinoma with highly heterogeneous, aggressive, and multidrug resistance has a poor prognosis. Although babaodan (BBD) combined with cisplatin improved non-small cell lung cancer efficacy...

查看原文本刊更多论文

巴巴丹通过抑制 YAP1 克服胆管癌的顺铂耐药性

胆管癌具有高度异质性、侵袭性和多药耐药性，预后较差。虽然巴巴丹（BBD）与顺铂联用可改善非小细胞肺癌的疗效...

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmaceutical Biology 医学-药学

CiteScore

6.70

自引率

2.60%

发文量

191

审稿时长

1 months

期刊介绍： Pharmaceutical Biology will publish manuscripts describing the discovery, methods for discovery, description, analysis characterization, and production/isolation (including sources and surveys) of biologically-active chemicals or other substances, drugs, pharmaceutical products, or preparations utilized in systems of traditional medicine. Topics may generally encompass any facet of natural product research related to pharmaceutical biology. Papers dealing with agents or topics related to natural product drugs are also appropriate (e.g., semi-synthetic derivatives). Manuscripts will be published as reviews, perspectives, regular research articles, and short communications. The primary criteria for acceptance and publication are scientific rigor and potential to advance the field.